Episodes
-
399: Hair-raising trial results, and Servier’s M&A wishlist
Not summarized yet
-
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
Not summarized yet
-
397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
Not summarized yet
-
396: A new trick for old science, and biotech VCs' scrambled playbook
Not summarized yet
-
395: Biotech investors' plea to Trump, and a busy M&A week
Not summarized yet
-
394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy
Not summarized yet
-
393: A conversation with the 'godfather' of biotech
Not summarized yet
-
392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
Not summarized yet
-
391: Breaching the IBD efficacy ceiling, and sham surgeries
Not summarized yet
-
390: FDA turmoil, election intrigue, AI, and more
Not summarized yet
-
389: Hims' Super Bowl fallout, and the FDA reverses course
Not summarized yet
-
388: The FDA's refusal to review Moderna's mRNA flu vaccine
Not summarized yet
-
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
Not summarized yet
-
From Drug Story: Lipitor and Heart Disease
Not summarized yet
-
386: The high stakes for Huntington's patients
Not summarized yet
-
385: A measles outbreak and hospitals' financial troubles
Not summarized yet
-
384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
Not summarized yet
-
383: JPM to bring more deals and happy CEOs
Not summarized yet
-
382: Biotech's year in review
Not summarized yet
-
381: The future of American science and a dispatch from ASH
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account